L-carnitine does not reduce cancer-related fatigue

L-carnitine does not reduce cancer-related fatigue
Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology.

(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology.

To determine whether L-carnitine improves fatigue in , Ricardo A. Cruciani, M.D., of the Beth Israel Medical Center in New York City, and colleagues conducted an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled study involving 376 patients with invasive malignancies who received either 2 g/day of L-carnitine oral supplement or matching placebo for four weeks.

The researchers found that fatigue, as measured using the Brief Fatigue Inventory, improved in both treatment arms compared with baseline, but there was no significant between-group difference. In a subgroup analysis, L-carnitine supplementation also did not improve fatigue in those who were carnitine-deficient at baseline. Neither depression nor pain was improved, as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue instrument. The improvement in both arms suggests a large .

"This is the largest clinical trial to date studying the effect of L-carnitine supplementation on patients with invasive and fatigue," the authors write. "In this phase III, randomized, double-blind, placebo-controlled study, we observed that 1 g twice daily of oral L-carnitine supplementation for four weeks does not improve fatigue, depression, or pain in patients with cancer."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Iron supplements can reduce fatigue in nonanemic women

Jul 09, 2012

Iron supplementation reduced fatigue by almost 50% in women who are low in iron but not anemic, according to the results of a clinical trial published July 9 in CMAJ (Canadian Medical Association Journal).

Ginseng fights fatigue in cancer patients, study finds

Jun 04, 2012

High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had ...

Web-Based program helps manage cancer-Related fatigue

Mar 13, 2012

(HealthDay) -- An Internet-based educational program helps disease-free cancer survivors better manage their cancer-related fatigue (CRF), according to research published online March 12 in the Journal of ...

Adding ketamine to opioids doesn't reduce cancer pain

Sep 11, 2012

(HealthDay)—Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it ...

Recommended for you

The fine line between breast cancer and normal tissues

13 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

14 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

16 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

18 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments